212628-46-1

Basic information

• Product Name: Benzoic acid, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-
• CAS NO: 212628-46-1
• Molecular Formula: C14H9BrF2INO2
• Molecular Weight: 468.036
• Mol File: 212628-46-1.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-(212628-46-1)
• EPA Substance Registry System: Benzoic acid, 5-bromo-3,4-difluoro-2-[(4-iodo-2-methylphenyl)amino]-(212628-46-1)

Safety Data

• Hazardous Substances Data: 212628-46-1(Hazardous Substances Data)

Upstream product

• 13194-68-8 4-iodo-2-methylaniline 
• 212631-85-1 3-bromo-4,5,6-trifluorobenzoic acid 

Downstream Products

• 219778-43-5 5-bromo-N-cyclohexylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide 
• 219778-40-2 5-bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-isobutoxy-benzamide 
• 219778-52-6 5-Bromo-N-cyclobutylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide 
• 219778-48-0 5-bromo-N-cyclopentylmethoxy-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzamide 
• 321438-68-0 5-bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-methoxy-benzamide 
• 391212-08-1 5-Bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid pentafluorophenyl ester 

Relevant articles and documents

A simple and efficient synthesis of 2-(N-phenylamino)-benzoic acids

A new method for the synthesis of 2-(N-phenylamino)benzoic acids is presented, with 2-fluorobenzoic acids and anilines as starting materials. Several experimental conditions as well as the factors influencing the outcome of the reaction are described.

Treatment of asthma with MEK inhibitors

This invention provides a method of preventing or treating asthma by administering to a patient in need of treatment an effective amount of a selective MEK inhibitor, especially a phenyl amine of Formula I and II:

Combination chemotherapy

Mitotic inhibitors such as paclitaxel have improved antitumor activity when used in combination with a selective MEK inhibitor, especially a phenyl amine compound of Formula I and II: